Risks Associated with Pregnancy Conceived by Artificial Ovulation
Pregnancies conceived after artificial ovulation induction carry increased risks of multiple gestation (the most significant concern), ovarian hyperstimulation syndrome (OHSS), preterm birth, low birthweight, and ectopic pregnancy, though the absolute risk of congenital malformations remains low and comparable to spontaneous conception.
Primary Maternal Risks
Multiple Pregnancy - The Dominant Risk
Multiple gestation represents the most clinically significant complication of ovulation induction, with rates varying substantially by medication type 1:
- Gonadotropins: Multiple pregnancy rates of 3.6-12.5%, including risk of triplets and higher-order multiples (up to 10 triplet pregnancies reported) 1
- Clomiphene citrate: 6-14% multiple pregnancy rate depending on follicle number; 7.98% overall (6.9% twins, 0.5% triplets, 0.3% quadruplets) 1, 2
- Letrozole: Lower multiple pregnancy rate (13% among ongoing pregnancies), with all multiples being twins 3
Critical risk stratification by follicle count: The risk escalates dramatically with multifollicular development. With 2,3, or 4 dominant follicles, multiple pregnancy rates increase to 6%, 14%, and 10% respectively 1.
Multiple pregnancies directly increase maternal morbidity through:
- Pre-eclampsia
- Gestational diabetes
- Cesarean delivery
- Postpartum hemorrhage
Ovarian Hyperstimulation Syndrome (OHSS)
OHSS represents a potentially life-threatening complication, particularly with gonadotropin therapy 1, 4:
Clinical manifestations include:
- Rapid fluid accumulation in peritoneal cavity, thorax, and pericardium
- Severe pelvic pain, nausea, vomiting, weight gain
- Hypovolemia, hemoconcentration, electrolyte imbalances
- Thromboembolic complications (venous thrombophlebitis, pulmonary embolism, stroke, arterial occlusion)
- Hepatic dysfunction
- Acute respiratory distress
Risk is highest when pregnancy occurs, as OHSS becomes more severe and protracted 4. Women with risk factors (obesity, thrombophilia, family history) face elevated thromboembolic risk during and after treatment.
Ovarian Torsion
Reported following gonadotropin treatment, particularly associated with OHSS, pregnancy, and ovarian cysts 4. Early diagnosis is critical to preserve ovarian function.
Fetal and Neonatal Risks
Preterm Birth and Low Birthweight
Individuals undergoing ovulation induction should be counseled about increased risk of preterm birth and low birthweight in both singleton and twin pregnancies compared to fertile couples 1:
- Singleton births after ovulation induction are approximately 1.5 times more likely to be preterm compared to spontaneous conception 1
- Birth weight is significantly lower (3,167g vs 3,251g, p=0.009) even when comparing the same mother's ovulation-induced versus spontaneous pregnancies 5
- Higher incidence of extreme prematurity (<32 weeks), very low birthweight (<1500g), and associated complications including respiratory distress syndrome 1
This appears related to altered placentation from supraphysiological hormonal exposure rather than underlying infertility alone 5.
Congenital Malformations
The absolute risk of congenital malformations remains low and does not appear significantly increased with ovulation induction agents:
- Clomiphene citrate: No association with increased major malformations (aOR 1.08,95% CI 0.88-1.32) or specific organ system defects 6. Clinical trial data showed <1% rate for most anomalies 2
- Letrozole: 2.15% overall malformation rate (95% CI 1.7-2.5%), with no significant increase versus clomiphene (RD 0.01,95% CI -0.02,0.03) 7
- Gonadotropins: Slightly higher incidence than spontaneous conception (25-50% increased relative risk), but absolute risk remains low. Most common systems affected: cardiovascular (25-40%), genitourinary (10-60%), gastrointestinal (10-20%), musculoskeletal (10-35%) 8
The slightly elevated risk with ART is thought related to parental characteristics (maternal age, sperm quality) and multiple gestations rather than medications themselves 4.
Ectopic Pregnancy
Infertile women undergoing assisted reproduction have increased ectopic pregnancy incidence 4, 9. Early ultrasound confirmation of intrauterine location is essential. Heterotopic pregnancy (simultaneous intrauterine and ectopic) risk increases with fertility treatments and can be easily missed 9.
Pregnancy Loss
- Spontaneous abortion risk is increased with gonadotropin products, though causality remains unestablished and may reflect underlying infertility 4
- Letrozole versus clomiphene: No increased pregnancy loss risk (RD -0.01,95% CI -0.06,0.04 in randomized trials) 7
Risk Mitigation Strategies
Primary Prevention of Multiple Pregnancy
Cycle cancellation criteria 1:
- Withhold IUI when >2 dominant follicles >15mm OR >5 follicles >10mm at time of hCG injection/LH surge
Medication selection and dosing 1:
- Gonadotropins: Use ≤75 IU regimens; higher doses increase multiple pregnancy rates without improving pregnancy rates
- Clomiphene citrate or tamoxifen: Acceptable alternatives with lower multiple pregnancy rates and costs, though lower live birth rates than gonadotropins
- Letrozole: Comparable efficacy to clomiphene with potentially lower multiple pregnancy risk (all multiples are twins) 3, 10
- Avoid GnRH agonist addition: Increases multiple pregnancy rates and costs without improving pregnancy rates 1
Secondary prevention: Aspiration of excess follicles at time of hCG injection as alternative to cycle cancellation 1
OHSS Prevention
- Close monitoring of ovarian response with ultrasound and serum estradiol 4
- Withhold hCG if OHSS developing
- Monitor for ≥2 weeks after hCG administration
- Hospitalize if severe OHSS develops
- Consider metformin in PCOS patients undergoing IVF to reduce OHSS risk 11
Medication-Specific Considerations
Gonadotropins: Highest pregnancy rates but greatest multiple pregnancy and OHSS risk. Requires intensive monitoring 4.
Clomiphene citrate: Established safety profile with no increased congenital malformation risk 2, 6. Multiple pregnancy rate 7.98% overall 2.
Letrozole: Emerging as preferred first-line agent with therapeutic benefits and no evidence of fetal harm 7. Lower multiple pregnancy risk than gonadotropins but lower live birth rate (18.7% vs 32.2%) 3. Recent evidence supports superior pregnancy outcomes and safety compared to clomiphene in IUI cycles 10.
Clinical Monitoring Recommendations
- Serial ultrasound for follicle monitoring and multiple pregnancy prevention
- Early pregnancy ultrasound to confirm intrauterine location and exclude heterotopic pregnancy
- Enhanced fetal growth monitoring given association with lower birthweight 5
- Detailed anatomic ultrasound and fetal echocardiogram consideration per ACOG recommendations for ART pregnancies 8
- Vigilance for preterm labor signs given 1.5-fold increased risk 1